Enhances transparency in the prescription drug supply chain
Impact
If enacted, A10967 would amend existing public health and education laws within New York State. It would require pharmacies to ensure that supply chain information related to the origin, manufacturing, and distribution of prescription drugs is accessible to patients at the point of dispensing. The bill also stipulates that pharmacy benefit managers maintain and provide this information upon request, further promoting accountability in the healthcare system.
Summary
A10967, known as the Foreign Drug Transparency Act, aims to enhance transparency in the prescription drug supply chain. The bill mandates that pharmacies provide detailed supply chain information about prescription drugs, including the country of origin of both the drugs and their active pharmaceutical ingredients (APIs). This legislation recognizes the increasing globalization of the drug supply chain and seeks to ensure that consumers, pharmacists, and healthcare providers have access to important information that affects patient safety and informed decision-making.
Contention
Despite its intentions, the bill has faced scrutiny regarding the feasibility and potential implications of requiring detailed supply chain disclosures. Some stakeholders express concerns that compliance could impose additional burdens on pharmacies and might complicate the existing regulatory landscape. There are also discussions about how these requirements align or conflict with federal laws governing drug labeling and regulation, given the preemptive nature of some federal statutes.
Additional_notes
The legislative intent of A10967 is to complement federal efforts aimed at improving drug labeling and transparency. By doing so, it seeks to provide consumers with information that supports their health and safety while also aligning state-level laws with ongoing federal initiatives.
Same As
Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.